Abstract
The cytochromes P450 superfamily of enzymes is a group of hemeproteins That catalyze the metabolism of an extensive series of compounds including drugs, chemical carcinogens, fatty acids, and steroids. They oxidize substrates ranging in size from ethylene to cyclosporin. Although significant efforts have been made to obtain structural information on the active sites of the microbial P450s, relatively little is currently known regarding the identities of the critical amino acid residues in the P450 active sites that are involved in substrate binding and catalysis. Since information on the crystal structures of the eukaryotic P450s has been relatively limited, investigators have used a variety of other techniques in attempts to elucide the structural features that play a role in the catalytic properties and substrate specificity at the enzyme active site. These include site-directed mutagenesis, natural mutations, homology modeling, mapping with aryl-iron complexes, affinity and photoaffinity labeling, and mechanism-based inactivators. A variety of different mechanism-based inactivators have proven to be useful in identifiying active site amino acid residues involved in substrate binding and catalysis. In this review we present a sampling of the types of studies that can be conducted using mechanism-based inactivators and highlight studies with several classes of compounds including acetylenes, isothiocyanates, xanthates, aminobenzotriazoles, phencyclidine, and furanocoumarins. Labeled peptides isolated from the inactivated proteins have been analyzed by N-terminal amino acid sequencing in conjunction with mass spectrometry to determine the sites of covalent modification. Mechanistic studies aimed at identifying the basis for the inactivation following adduct formation are also presented.
Keywords: Cytochrome P450, homology modeling, Mapping, aminobenzotriazoles, phencyclidine, furanocoumarins, Acetylenes, isothiocyanates, xanthates, 2-ethynylnaphthalene, 9-ethynylphenanthrene
Current Drug Metabolism
Title: Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function
Volume: 2 Issue: 3
Author(s): Ute M. Kent, Monica I. Jushchhyshyn and Paul F. Hollenberg
Affiliation:
Keywords: Cytochrome P450, homology modeling, Mapping, aminobenzotriazoles, phencyclidine, furanocoumarins, Acetylenes, isothiocyanates, xanthates, 2-ethynylnaphthalene, 9-ethynylphenanthrene
Abstract: The cytochromes P450 superfamily of enzymes is a group of hemeproteins That catalyze the metabolism of an extensive series of compounds including drugs, chemical carcinogens, fatty acids, and steroids. They oxidize substrates ranging in size from ethylene to cyclosporin. Although significant efforts have been made to obtain structural information on the active sites of the microbial P450s, relatively little is currently known regarding the identities of the critical amino acid residues in the P450 active sites that are involved in substrate binding and catalysis. Since information on the crystal structures of the eukaryotic P450s has been relatively limited, investigators have used a variety of other techniques in attempts to elucide the structural features that play a role in the catalytic properties and substrate specificity at the enzyme active site. These include site-directed mutagenesis, natural mutations, homology modeling, mapping with aryl-iron complexes, affinity and photoaffinity labeling, and mechanism-based inactivators. A variety of different mechanism-based inactivators have proven to be useful in identifiying active site amino acid residues involved in substrate binding and catalysis. In this review we present a sampling of the types of studies that can be conducted using mechanism-based inactivators and highlight studies with several classes of compounds including acetylenes, isothiocyanates, xanthates, aminobenzotriazoles, phencyclidine, and furanocoumarins. Labeled peptides isolated from the inactivated proteins have been analyzed by N-terminal amino acid sequencing in conjunction with mass spectrometry to determine the sites of covalent modification. Mechanistic studies aimed at identifying the basis for the inactivation following adduct formation are also presented.
Export Options
About this article
Cite this article as:
Kent M. Ute, Jushchhyshyn I. Monica and Hollenberg F. Paul, Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function, Current Drug Metabolism 2001; 2 (3) . https://dx.doi.org/10.2174/1389200013338478
DOI https://dx.doi.org/10.2174/1389200013338478 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Thinking Outside the ‘Block’: Alternative Polymer Compositions for Micellar Drug Delivery
Current Topics in Medicinal Chemistry Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Current Topics in Medicinal Chemistry Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Smoking and Eye Pathologies. A Systemic Review. Part I. Anterior Eye Segment Pathologies
Current Pharmaceutical Design The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Environmental Factors and Hypertension
Current Pharmaceutical Design The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design An Inventive Report of Inducing Apoptosis in Non-Small Cell Lung Cancer (NSCLC) Cell Lines by Transfection of MiR-4301
Anti-Cancer Agents in Medicinal Chemistry Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia via mir-491
Anti-Cancer Agents in Medicinal Chemistry Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Biologic Therapy in Rheumatoid Arthritis
Current Topics in Medicinal Chemistry The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19
Current Pharmaceutical Design